Jiangsu Hillgene Biopharma

Hillgene Biopharma is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the cell and gene therapy (CGT) sector. Headquartered in Suzhou, China, the company provides comprehensive services including process development, analytical testing, and GMP-compliant manufacturing. Their expertise covers plasmid DNA, viral vectors such as Lentivirus and AAV, and various cell therapies including CAR-T, TCR-T, and NK cells. Hillgene's facilities are designed to meet global regulatory standards from the NMPA, FDA, and EMA, enabling biopharma partners to transition from preclinical research to commercial-scale production. The company offers an integrated platform that significantly reduces the time and cost associated with CGT development. By providing scalable solutions for complex biologics, Hillgene plays a critical role in accelerating the delivery of innovative treatments to patients worldwide.